Jingxin Pharmaceutical

Zhejiang Jingxin Pharmaceutical Co., Ltd. (Securities Code: 002020), founded in 1990, is a listed pharmaceutical company integrating R&D, production, and sales. Adhering to the core corporate values of "Pragmatism, Innovation, Inclusiveness, and Win-Win" and committed to the mission of "Carefully Guarding Health," the company strives to become a leader in China's psychiatric/neurological and cardiovascular/cerebrovascular fields.

As of now, the company has a registered capital of RMB 860 million and total assets of RMB 8.124 billion. With headquarters in both Xinchang and Hangzhou, the company operates seven production bases: formulation production bases in Xinchang, API production bases in Shangyu and Weifang (Shandong), traditional Chinese medicine production bases in Bayannur (Inner Mongolia) and Shaxi (Guangdong), and medical device production bases in Shenzhen and Shenyang. It has also invested in and established cooperative companies and R&D laboratories in the United States, Israel, South Korea, and other countries. The company employs over 3,700 people, including more than 270 with master's or doctoral degrees.

Upholding the production quality philosophy of "Jingxin Medicine, Meticulously Made," the company has fully passed the new GMP certification. Its solid dosage form production line was the first to pass German GMP certification in 2006, and it passed the US FDA on-site inspection in 2018. With rapidly improving overall economic efficiency, the company has been listed for many consecutive years on the "China Chemical Pharmaceutical Industry Top Export-Oriented Enterprise Brands for Formulations," "Top 100 Chinese Pharmaceutical Enterprises," and "Top 100 Chinese Chemical Pharmaceutical Enterprises." It is one of the first batch of "Pioneer Enterprises for Internationalization of Formulations among Chinese Pharmaceutical Companies" and one of the first batch of units undertaking outstanding topics under the national "Major New Drug Creation" Science and Technology Major Project, with ever-increasing social visibility and reputation.

The company is a national key high-tech enterprise, possessing a national enterprise technology center, a post-doctoral research workstation, a provincial key enterprise research institute, a provincial academician and expert workstation, and a provincial high-tech enterprise R&D center. It has established an innovative drug R&D center in Zhangjiang, Shanghai, and a biopharmaceutical and API R&D center in Hangzhou. It maintains long-term, sound exchange and cooperation relationships with renowned domestic and international research institutes, R&D companies, and universities, including the Shanghai Institute of Pharmaceutical Industry, the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, and Zhejiang University. With strong scientific and technological capabilities, the company has achieved fruitful R&D results, holding 8 national key new products and undertaking 9 National Torch Plan projects.

As of December 31, 2025, the company has accumulated a total of 236 patented technologies, including 168 invention patents (156 domestic invention patents, 3 US invention patents, 3 European invention patents, 3 Japanese invention patents, 1 South Korean invention patent, 1 Hong Kong invention patent, and 1 Russian invention patent), 53 utility model patents, and 15 design patents, reflecting its strong R&D strength and innovation capability.